San Diego, CA., September 22, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be hosting an exhibition table at the 6th Fire, Ice and Beyond: The Future of Ablation Therapies conference in Las Vegas, NV, September 23-24. OncoSec’s exhibition will highlight a poster presentation providing preliminary results from their phase IV head and neck cancer and phase I breast cancer trials carried out in Europe using OncoSec’s OMS ElectroChemotherapy™ treatment approach.
“We are pleased to highlight at this important scientific conference the extent of our clinical development activities of our OMS ElectroChemotherapy™ program and begin to share validating data from prior clinical trials that supports the merits of the therapy,” said Punit Dhillon, president and CEO of OncoSec. “Our aim is to complete data analysis from the previous OMS ElectroChemotherapy™ programs and present this clinical data at applicable oncology and scientific meetings and seek a commercialization path for the product with the help of one or more industry partnerships from select geographic regions or globally.”
Through its asset acquisition, OncoSec has accumulated a significant database of clinical data in a variety of tumor types using the OMS ElectroChemotherapy™ therapeutic approach. To date OMS ElectroChemotherapy™ has been tested in several clinical trials ranging from Phase I through Phase IV conducted in 13 countries across over 50 sites. Human data has been collected in over 400 patients with cancers ranging from basal and squamous cell carcinomas, melanoma, adenocarcinoma, Kaposi’s sarcoma, pancreatic, hepatic, oral, and head and neck cancers.
The 6th Fire, Ice, and Beyond: The Future of Ablation Therapies is an advanced program presenting guidance in understanding the expanding field of new and cutting edge energy sources, combination therapies, embolic pharmaceuticals, treatment planning, fusion imaging, and navigation that make up Interventional Oncology procedures. This conference will be attended by physicians, scientists, and business executives in their areas of expertise.
OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.